NCT00934089View on ClinicalTrials.gov

A Phase 2 Study Of The 24-Hour Intraocular Pressure Lowering And Systemic Exposure Of PF-04217329

PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

June 30, 2010

Study Completion Date

June 30, 2010

Conditions
Glaucoma, Open-AngleOcular Hypertension
Interventions
DRUG

PF-04217329

Topical ocular solution, once-daily for 14 days

DRUG

latanoprost vehicle

Topical ocular solution, once-daily for 14 days

DRUG

PF-04217329

Topical ocular solution, once-daily for 14 days

DRUG

latanoprost

Topical ocular solution, once-daily for 14 days

Trial Locations (8)

90013

East-West Eye Institute, Los Angeles

90057

Los Angeles Eye Medical Group, Los Angeles

90247

East-West Eye Institute, Gardena

90630

West Coast Clinical Trials, LLC, Cypress

90806

Ophthalmology Corporation, Long Beach

91105

Southern California Glaucoma Consultants, Pasadena

92663

Eye Research Foundation, Newport Beach

92844

Glory Medical Group, Garden Grove

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY